Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 1, 2011
Grant Date -
Oct 18, 2007
app pub date -
Feb 13, 2007
filing date -
Feb 13, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The present invention discloses the link between oncogenic Ras and TSG101 and the negative effect of TSG101 on the expression of p21 in ovarian cancer. The present also discloses the use of TSG101 as a prognostic, diagnostic marker and a potential therapeutic target in cancer, especially ovarian cancer.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully